MA41051A - Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose - Google Patents

Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose

Info

Publication number
MA41051A
MA41051A MA041051A MA41051A MA41051A MA 41051 A MA41051 A MA 41051A MA 041051 A MA041051 A MA 041051A MA 41051 A MA41051 A MA 41051A MA 41051 A MA41051 A MA 41051A
Authority
MA
Morocco
Prior art keywords
transmembranary
mucoviscidosis
conductance regulator
modulators
regulator modulators
Prior art date
Application number
MA041051A
Other languages
English (en)
Other versions
MA41051B1 (fr
Inventor
Corey Anderson
Vijayalaksmi Arumugam
Brian Richard Bear
Hayley Marie Binch
Jeremy J Clemens
Thomas Cleveland
Erica Conroy
Timothy Richard Coon
Bryan A Frieman
Peter Diederik Jan Grootenhuis
Raymond Stanley Gross
Sara Sabina Hadida-Ruah
Pramod Virupax Joshi
Haripada Khatuya
Paul John Krenitsky
Chun-Chieh Lin
Gulin Erdogan Marelius
Jason Mccartney
Vito Melillo
Mark Thomas Miller
Georgia Mcgaughey Nicholls
Fabrice Jean Denis Pierre
Alina Silina
Andreas P Termin
Johnny Uy
Jinglan Zhou
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55631997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41051(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MA41051A publication Critical patent/MA41051A/fr
Publication of MA41051B1 publication Critical patent/MA41051B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C07D209/49—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide and having in the molecule an acyl radical containing a saturated three-membered ring, e.g. chrysanthemumic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La présente invention concerne un composé de formule (i): (i) ou un sel pharmaceutiquement acceptable de celui-ci, où r1, r2, r3, w, x, y, z, n, o, p et q sont tels que définis dans la description, lequel composé est utile pour le traitement de maladies médiées par le cftr, telles que la mucoviscidose. La présente invention concerne également des compositions pharmaceutiques, une méthode de traitement et des kits correspondants.
MA41051A 2014-10-06 2015-10-06 Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose MA41051B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462060182P 2014-10-06 2014-10-06
US201562114767P 2015-02-11 2015-02-11
US201562153120P 2015-04-27 2015-04-27
PCT/US2015/054316 WO2016057572A1 (fr) 2014-10-06 2015-10-06 Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose

Publications (2)

Publication Number Publication Date
MA41051A true MA41051A (fr) 2017-08-16
MA41051B1 MA41051B1 (fr) 2020-11-30

Family

ID=55631997

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41051A MA41051B1 (fr) 2014-10-06 2015-10-06 Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
MA054649A MA54649A (fr) 2014-10-06 2015-10-06 Modulateurs de régulateur de conductance transmembranaire de la fibrose kystique

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA054649A MA54649A (fr) 2014-10-06 2015-10-06 Modulateurs de régulateur de conductance transmembranaire de la fibrose kystique

Country Status (29)

Country Link
US (5) US9782408B2 (fr)
EP (3) EP3798214B1 (fr)
JP (2) JP6896619B2 (fr)
KR (1) KR102336926B1 (fr)
CN (3) CN112250627B (fr)
AU (3) AU2015328174B2 (fr)
CA (1) CA2963792A1 (fr)
CL (1) CL2017000824A1 (fr)
CO (1) CO2017004538A2 (fr)
CY (1) CY1123487T1 (fr)
DK (1) DK3203840T3 (fr)
ES (1) ES2823850T3 (fr)
HR (1) HRP20201603T1 (fr)
HU (1) HUE051972T2 (fr)
IL (2) IL251517A0 (fr)
LT (1) LT3203840T (fr)
MA (2) MA41051B1 (fr)
MX (2) MX2017004543A (fr)
NZ (3) NZ730794A (fr)
PL (1) PL3203840T3 (fr)
PT (1) PT3203840T (fr)
RS (1) RS60906B1 (fr)
RU (1) RU2020134082A (fr)
SG (3) SG10201913603QA (fr)
SI (1) SI3203840T1 (fr)
TW (2) TWI735416B (fr)
UA (1) UA125245C2 (fr)
WO (1) WO2016057572A1 (fr)
ZA (1) ZA201703054B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
RU2008109031A (ru) 2005-08-11 2009-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы муковисцидозного трансмембранного регулятора проводимости
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
DK3091011T3 (en) 2006-04-07 2018-02-26 Vertex Pharma MODULATORS OF ATP BINDING CASSETTE TRANSPORT
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
ES2445447T3 (es) 2007-11-16 2014-03-03 Vertex Pharmaceuticals Inc. Moduladores de isoquinolina de transportadores de casete de unión a ATP
CA2707494C (fr) 2007-12-07 2018-04-24 Vertex Pharmaceuticals Incorporated Procedes de fabrication d'acides cycloalkylcarboxamido-pyridine benzoiques
KR20100101130A (ko) 2007-12-07 2010-09-16 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
NZ602030A (en) 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
EP2821400B1 (fr) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Procédé pour faire des modulateurs de régulateur de conductance transmembranaire de la fibrose kystique
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
WO2013130669A1 (fr) 2012-02-27 2013-09-06 Vertex Pharmaceuticals Incorporated Composition pharmaceutique et son administration
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CN112250627B (zh) * 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
AU2015330923B2 (en) 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
BR112018007145A2 (pt) 2015-10-09 2018-11-06 AbbVie S.à.r.l. ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso
ES2946970T3 (es) * 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
EP3519401B1 (fr) * 2016-09-30 2021-09-29 Vertex Pharmaceuticals Incorporated Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
IL277491B (en) * 2016-12-09 2022-08-01 Vertex Pharma Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
EP3634402A1 (fr) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
CA3068609A1 (fr) 2017-07-01 2019-01-10 Vertex Pharmaceuticals Incorporated Compositions et methodes de traitement de la fibrose kystique
US20200171015A1 (en) 2017-07-17 2020-06-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US20210228489A1 (en) * 2017-12-04 2021-07-29 Vertex Pharmaceuticals Incorporated Compositions for treating cystic fibrosis
MX2020005753A (es) * 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) * 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MD3752510T2 (ro) * 2018-02-15 2023-06-30 Vertex Pharma Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora
WO2019191620A1 (fr) 2018-03-30 2019-10-03 Vertex Pharmaceuticals Incorporated Formes cristallines de modulateurs de cftr
US20210139514A1 (en) 2018-04-05 2021-05-13 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3774825A1 (fr) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
JP7383012B2 (ja) * 2018-08-31 2023-11-17 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用
GB201817038D0 (en) * 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
FI3880197T3 (fi) 2018-11-14 2023-05-04 Vertex Pharma Menetelmiä kystisen fibroosin hoitamiseksi
EP3897832B1 (fr) * 2018-12-18 2023-10-11 Novartis AG Dérivés n-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide et leur utilisation dans le traitement d'une maladie médiée par cftr
CN109608415B (zh) * 2019-01-21 2020-12-01 暨南大学 噻唑甲酰胺类化合物及其合成和应用
UY38630A (es) * 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (fr) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Formes solides de modulateurs de cftr
BR112022002605A2 (pt) 2019-08-14 2022-05-03 Vertex Pharma Formas cristalinas de moduladores de cftr
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN110776616B (zh) * 2019-10-26 2021-06-22 福建华夏蓝新材料科技有限公司 一种高效润湿水性异氰酸酯固化剂
EP4058434A1 (fr) 2019-11-12 2022-09-21 Genzyme Corporation Hétéroarylaminosulfonamides à 6 chaînons pour le traitement de maladies et d'états médiés par une activité cftr déficiente
WO2021113806A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
WO2021113809A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
WO2021132577A1 (fr) * 2019-12-27 2021-07-01 日本たばこ産業株式会社 Composé acylsulfamide et son utilisation pharmaceutique
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US20230303589A1 (en) 2020-08-13 2023-09-28 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
AU2021329507A1 (en) 2020-08-20 2023-03-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating respiratory diseases characterized by mucus hypersecretion
PE20231108A1 (es) * 2020-10-07 2023-07-19 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
CN113402499B (zh) * 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
WO2023023376A2 (fr) * 2021-08-19 2023-02-23 University Of Virginia Patent Foundation Sulfonyl-triazoles utiles en tant que ligands de kinases covalents
WO2023034992A1 (fr) 2021-09-03 2023-03-09 Genzyme Corporation Composés indoles et procédés d'utilisation
WO2023034946A1 (fr) 2021-09-03 2023-03-09 Genzyme Corporation Composés indoles et leurs utilisations dans le traitement de la fibrose kystique
WO2023150236A1 (fr) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Procédés de préparation et formes cristallines de (6a,12a)-17-amino-12-méthyl-6,15-bis(trifluorométhyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadéca-1(18),2,4,14,16-pentaén-6-ol
WO2023150237A1 (fr) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
WO2023154291A1 (fr) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2023211990A1 (fr) * 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Inhibiteurs d'amides hétérocycliques bicycliques de na v1.8 pour le traitement de la douleur
CN115611693B (zh) * 2022-05-12 2023-11-28 常州大学 一种催化合成异色满-1-酮类或芳香酮类化合物的方法
WO2023224931A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
WO2023224924A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Formes solides de composés macrocycliques en tant que modulateurs de cftr et leur préparation
WO2024054851A1 (fr) 2022-09-07 2024-03-14 Sionna Therapeutics Composés macrocycliques, compositions et méthodes d'utilisation associées
WO2024054845A1 (fr) 2022-09-07 2024-03-14 Sionna Therapeutics Composés macrocycliques, compositions et leurs procédés d'utilisation
WO2024054840A1 (fr) 2022-09-07 2024-03-14 Sionna Therapeutics Composés macrocycliques, compositions et procédés d'utilisation associés
WO2024056791A1 (fr) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Association de modulateurs de cftr macrocycliques avec des correcteurs de cftr et/ou des potentialisateurs de cftr
WO2024056798A1 (fr) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Modulateurs du cftr macrocycliques

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194599A3 (fr) 1985-03-14 1988-01-20 Nissan Chemical Industries Ltd. Dérivés de benzamide, leur procédé de préparation et fongicides pour le sol les contenant
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
DE4410453A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9514160D0 (en) 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
PL321244A1 (en) 1995-01-19 1997-11-24 Ciba Geigy Ag Insecticide composition
EA001418B1 (ru) 1995-11-23 2001-02-26 Новартис Аг Гербицидная композиция
AU707574B2 (en) 1995-12-15 1999-07-15 Merck Frosst Canada & Co. Tri-aryl ethane derivatives as PDE IV inhibitors
JP2000516958A (ja) 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
JPH10114654A (ja) 1996-10-09 1998-05-06 Fujisawa Pharmaceut Co Ltd 新規用途
AU6209098A (en) 1997-01-15 1998-08-07 Novartis Ag Herbicidal agent
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DE19742951A1 (de) 1997-09-29 1999-04-15 Hoechst Schering Agrevo Gmbh Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung
US5972995A (en) 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
DE19802697A1 (de) 1998-01-24 1999-07-29 Bayer Ag Selektive Herbizide auf Basis von N-Aryl-triazolin(thi)onen und N-Arylsulfonylamino(thio)carbonyltriazolin(thi)onen
WO1999041238A1 (fr) 1998-02-13 1999-08-19 Kureha Kagaku Kogyo K.K. Derives de n-(pnenylsulfonyle) picolinamide, procede de production de ces derniers et herbicide
WO1999051574A1 (fr) 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Derives d'indole
MXPA01011112A (es) 1999-06-10 2002-06-04 Warner Lambert Co Metodo para la inhibicion de la agregacion de las proteinas amiloides y formacion de imagenes de los depositos amiloides utilizando derivados de la isoindolina.
DE19936438A1 (de) 1999-08-03 2001-02-08 Aventis Cropscience Gmbh Kombinationen von Herbiziden und Safenern
DE19940860A1 (de) 1999-08-27 2001-03-01 Bayer Ag Selektive Herbizide auf Basis eines substituierten Phenylsulfonyl aminocarbonyltriazolinons und Safenern II
DE19958381A1 (de) 1999-12-03 2001-06-07 Bayer Ag Herbizide auf Basis von N-Aryl-uracilen
AU2001229501A1 (en) 2000-01-24 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
WO2002015902A1 (fr) 2000-08-23 2002-02-28 Merck & Co., Inc. Procede pour traiter et prevenir l'incontinence urinaire par utilisation d'antagonistes de recepteur ep1 de prostanoide
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
MXPA03003174A (es) 2000-10-10 2003-07-14 Smithkline Beecham Corp Indoles substituidos, composiciones farmaceuticas que contienen dichos indoles y su uso como agentes de enlace ppar-y..
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
DE10119721A1 (de) 2001-04-21 2002-10-31 Bayer Cropscience Gmbh Herbizide Mittel enthaltend Benzoylcyclohexandione und Safener
DK1395566T3 (da) 2001-05-31 2008-01-07 Vicore Pharma Ab Tricycliske forbindelser, der er nyttige som angiotensin Il-agonister
AU2002307839B2 (en) 2001-06-28 2006-03-16 Zoetis P Llc Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion
DE10145019A1 (de) 2001-09-13 2003-04-03 Bayer Cropscience Gmbh Kombinationen aus Herbiziden und Safenern
DE10146873A1 (de) 2001-09-24 2003-04-17 Bayer Cropscience Gmbh Heterocyclische Amide und -Iminderivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
ES2234451T1 (es) 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
EP1447096A1 (fr) 2001-11-19 2004-08-18 Ono Pharmaceutical Co., Ltd. Remedes pour la frequence urinaire
DE10157545A1 (de) 2001-11-23 2003-06-12 Bayer Cropscience Gmbh Herbizide Mittel enthaltend Benzoylpyrazole und Safener
JP4471842B2 (ja) 2002-03-27 2010-06-02 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー アミド化合物および該化合物を用いる方法
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
MXPA04012252A (es) 2002-06-08 2005-02-25 Bayer Cropscience Gmbh Combinaciones de acidos carboxilicos aromaticos herbicidas y de antidotos.
DE10237461A1 (de) 2002-08-16 2004-02-26 Bayer Cropscience Gmbh Herbizide Mittel enthaltend Benzoylpyrazole und Safener
EP1536794A2 (fr) 2002-09-06 2005-06-08 Merck & Co., Inc. Traitement de la polyarthrite rhumatoide par inhibition de pde4
JP4977319B2 (ja) 2002-09-30 2012-07-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 嚢胞性線維症膜コンダクタンス制御因子蛋白質阻害薬およびその使用方法
CA2503063A1 (fr) 2002-10-22 2004-05-06 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Inhibiteurs selectifs de la cyclo-oxygenase-2 liberant de l'oxyde nitrique
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
AU2003302106A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
BR0317323A (pt) 2002-12-20 2005-11-16 Pfizer Prod Inc Inibidores de proteìna de transferência de triglicerìdeos microssomal
BR0317426A (pt) 2002-12-20 2005-11-16 Pfizer Prod Inc Inibidores de proteìna de transferência de triglicéridos microssomais
JP2006519258A (ja) 2003-02-28 2006-08-24 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ｉｉ受容体拮抗薬
WO2004080972A1 (fr) 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated Pyrazoles, modulateurs de transporteurs de cassettes de liaison a l'atp
WO2004085420A1 (fr) 2003-03-24 2004-10-07 Vicore Pharma Ab Composes bicycliques utiles en tant qu'agonistes d'angiotensine ii
ES2770035T3 (es) 2003-04-11 2020-06-30 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
WO2004110352A2 (fr) 2003-05-16 2004-12-23 The Regents Of The University Of California Composes accroissant le transport d'ions par des cftr de mutants, et leurs utilisations
DE602004022819D1 (de) 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005049593A2 (fr) * 2003-11-13 2005-06-02 Abbott Laboratories Promoteurs de l'apoptose contenant n-acylsulfonamide
CN1925854A (zh) 2003-11-14 2007-03-07 沃泰克斯药物股份有限公司 可用作atp－结合弹夹转运蛋白调控剂的噻唑和噁唑
GB0328024D0 (en) 2003-12-03 2004-01-07 Glaxo Group Ltd Compounds
AU2005207037A1 (en) 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
JP4960708B2 (ja) 2004-01-30 2012-06-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
KR100799802B1 (ko) 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
US20050197376A1 (en) 2004-03-02 2005-09-08 Fujisawa Pharmaceutical Co. Ltd. Concomitant drugs
ES2526614T3 (es) 2004-03-05 2015-01-13 Nissan Chemical Industries, Ltd. Compuesto de benzamida sustituida con isoxazolina y agente de control de organismos nocivos
WO2005099705A2 (fr) 2004-03-24 2005-10-27 Bayer Pharmaceuticals Corporation Preparation de derives imidazoles et leurs procedes d'utilisation
BRPI0509282A (pt) 2004-03-30 2007-09-18 Univ California compostos contendo hidrazida inibidores de cftr e seus usos
GB0410121D0 (en) 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds
EP1765347A4 (fr) 2004-06-04 2008-10-01 Univ California Composes intervenant dans l'acceleration du transport ionique par le cftr mutant, et utilisations desdits composes
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
ME02970B (fr) 2004-06-24 2018-07-20 Vertex Pharma Modulateurs de transporteurs de cassette de liaison a l ́ATP
WO2006030807A1 (fr) 2004-09-15 2006-03-23 Shionogi & Co., Ltd. Dérivé de carbamoylpyridone ayant une activité d'inhibition de la vih intégrase
EP1812429A4 (fr) 2004-09-29 2010-07-21 Portola Pharm Inc 2h-1,3-benzoxazin-4(3h)-ones substitues
EP1812071A2 (fr) 2004-10-13 2007-08-01 PTC Therapeutics, Inc. Les composes pour la suppression de non-sens et l'emploi de ces composes pour la production d'un medicament pour le traitement des maladies somatiques causes par les mutations
WO2006065204A1 (fr) 2004-12-14 2006-06-22 Astrazeneca Ab Aminopyridines substituees et utilisations
MX2007007330A (es) * 2004-12-16 2007-10-04 Vertex Pharma Piridonas de utilidad como inhibidores de quinasas .
AR052429A1 (es) 2004-12-23 2007-03-21 Glaxo Group Ltd Compuesto de arilpiridina, composicion farmaceutica que lo comprende, su uso para l a eleboracion de un medicamento y procedimiento para prepararlo
GB0428173D0 (en) * 2004-12-23 2005-01-26 Astrazeneca Ab Compounds
EP1865949B1 (fr) 2005-03-11 2012-11-14 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison à l'ATP
AU2006227833A1 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
MX2007012206A (es) 2005-04-08 2007-12-05 Ptc Therapeutics Inc Composiciones de 1,2,4-oxadiazol activo por via oral para terapia de supresion de mutacion interruptora.
AU2006251624A1 (en) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
US20070032488A1 (en) 2005-08-05 2007-02-08 Genelabs Technologies, Inc. 6-Membered aryl and heteroaryl derivatives for treating viruses
RU2008109031A (ru) 2005-08-11 2009-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы муковисцидозного трансмембранного регулятора проводимости
CA2624683A1 (fr) 2005-10-06 2007-04-19 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l'atp
WO2007053641A2 (fr) 2005-11-01 2007-05-10 Mars, Incorporated Procyanidines de type a et inflammation
CA2635214A1 (fr) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Composes utiles dans les bio-essais cftr et leurs procedes
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
NZ569327A (en) 2005-12-28 2011-09-30 Vertex Pharma 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
WO2007113327A2 (fr) 2006-04-05 2007-10-11 Bayer Cropscience Sa Dérivés de n-cyclopropylsulfonylamide fongicides
DK3091011T3 (en) 2006-04-07 2018-02-26 Vertex Pharma MODULATORS OF ATP BINDING CASSETTE TRANSPORT
WO2007134279A2 (fr) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions de n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoléine-3-carboxamide
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
AU2007351454B2 (en) 2006-11-03 2013-07-18 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
MX2009008439A (es) 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
WO2008141385A1 (fr) 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Inhibiteurs de polymérases virales
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8173810B2 (en) 2007-05-25 2012-05-08 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
KR20100049667A (ko) * 2007-08-29 2010-05-12 쉐링 코포레이션 바이러스 감염 치료용 2,3-치환된 인돌 유도체
AU2008301907B2 (en) 2007-09-14 2014-02-20 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2705586A1 (fr) 2007-11-16 2009-05-22 Schering Corporation Derives d'indole a substitution heterocyclique en position 3 et leurs procedes d'utilisation
AU2013231151B2 (en) 2007-11-16 2015-06-25 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-Binding Cassette transporters
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
KR20100101130A (ko) 2007-12-07 2010-09-16 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
CA2707494C (fr) 2007-12-07 2018-04-24 Vertex Pharmaceuticals Incorporated Procedes de fabrication d'acides cycloalkylcarboxamido-pyridine benzoiques
AU2013270464B2 (en) 2008-03-31 2016-05-26 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
CN102036952A (zh) 2008-04-16 2011-04-27 比奥里波克斯公司 用作药物的双芳基化合物
US20110112193A1 (en) 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
US8888400B2 (en) * 2010-10-07 2014-11-18 Mcgard Llc Corrosion-resistant self-locking manhole cover
EP2145537A1 (fr) 2008-07-09 2010-01-20 Bayer CropScience AG Régulateur de croissance végétale
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
JP5575768B2 (ja) 2008-08-13 2014-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド 薬学的組成物およびその投与
EP2326178A4 (fr) 2008-08-21 2012-10-24 Glaxosmithkline Llc Inhibiteurs de la prolyl-hydroxylase
MX2011002149A (es) 2008-08-27 2011-04-05 Calcimedica Inc Compuestos que modulan el calcio intracelular.
US9333235B2 (en) 2008-10-22 2016-05-10 Trustees Of Dartmouth College Combination therapy and kit for the prevention and treatment of cystic fibrosis
AU2009308284B2 (en) 2008-10-23 2016-02-04 Vertex Pharmaceuticals, Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
DK2365972T3 (en) 2008-11-06 2015-01-19 Vertex Pharma Modulators of atp-binding cassette conveyors
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2382197B1 (fr) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
RU2539587C2 (ru) 2009-01-19 2015-01-20 Эббви Инк. Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
CN103641709B (zh) 2009-03-11 2017-08-25 拜耳知识产权有限责任公司 被卤代烷基亚甲基氧基苯基取代的酮烯醇
EP2821400B1 (fr) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Procédé pour faire des modulateurs de régulateur de conductance transmembranaire de la fibrose kystique
RU2518897C2 (ru) 2009-03-20 2014-06-10 Вертекс Фармасьютикалз Инкорпорейтед Производные 3-карбоксамида-4-оксохинолина, полезные в качестве модуляторов регулятора трансмембранной проводимости кистозного фиброза
WO2010110231A1 (fr) 2009-03-26 2010-09-30 塩野義製薬株式会社 Dérivé de 3-hydroxy-4-pyridone substitué
CN102458122A (zh) * 2009-04-20 2012-05-16 人类健康研究所 含有哒嗪磺胺衍生物的化合物、组合物和方法
TWI537269B (zh) 2009-05-26 2016-06-11 艾伯維巴哈馬有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘發劑
WO2011102514A1 (fr) 2010-02-22 2011-08-25 武田薬品工業株式会社 Composé cyclique aromatique
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
CA2792207A1 (fr) 2010-03-19 2011-09-22 Vertex Pharmaceuticals Incorporated Formes solides de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
PL3835297T3 (pl) 2010-03-25 2023-09-11 Vertex Pharmaceuticals Incorporated Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
RU2579370C2 (ru) 2010-04-07 2016-04-10 Вертекс Фармасьютикалз Инкорпорейтед Твердые формы 3-(2, 2-дифторбензо[d][1, 3] диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
US8344137B2 (en) 2010-04-14 2013-01-01 Hoffman-La Roche Inc. 3,3-dimethyl tetrahydroquinoline derivatives
EP2560649A1 (fr) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CN103153287A (zh) 2010-08-23 2013-06-12 弗特克斯药品有限公司 (R)-1-(2，2-二氟苯并[d][1，3]间二氧杂环戊烯-5-基)-N-(1-(2，3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用
EP2608775A2 (fr) 2010-08-27 2013-07-03 Vertex Pharmaceuticals Incorporated Composition pharmaceutique et ses administrations
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
WO2012078902A2 (fr) 2010-12-08 2012-06-14 Proteostasis Therapeutics, Inc. Régulateurs de la protéostasie
WO2012078909A1 (fr) 2010-12-08 2012-06-14 Proteostasis Therapeutics, Inc. Régulateurs thiazolpyrimidine de protéostasie
WO2012087938A1 (fr) 2010-12-20 2012-06-28 Glaxosmithkline Llc Dérivés de quinazolinone en tant qu'agents antiviraux
EP2471363A1 (fr) 2010-12-30 2012-07-04 Bayer CropScience AG Utilisation d'acides aryl-, hétéroaryl- et benzylsulfonaminés, d'esters d'acide aminé, d'amides d'acide aminé et carbonitrile ou leurs sels pour l'augmentation de la tolérance au stress dans des plantes
JPWO2012102297A1 (ja) 2011-01-26 2014-06-30 杏林製薬株式会社 ピラゾロピリジン誘導体、またはその薬理学的に許容される塩
US9000026B2 (en) 2011-02-17 2015-04-07 Bayer Intellectual Property Gmbh Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy
CA2828639C (fr) 2011-03-01 2019-02-12 Bayer Intellectual Property Gmbh 2-acyloxy-pyrrolin-4-ones
AR085585A1 (es) 2011-04-15 2013-10-09 Bayer Cropscience Ag Vinil- y alquinilciclohexanoles sustituidos como principios activos contra estres abiotico de plantas
WO2012154880A1 (fr) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Régulateurs de protéostasie pour le traitement de la mucoviscidose et autres maladies de mauvais repliement des protéines
WO2012154888A1 (fr) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Composés pour le traitement de troubles de repliement des protéines
WO2012154967A1 (fr) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Régulateurs de la protéostasie
MX349159B (es) 2011-05-18 2017-07-14 Concert Pharmaceuticals Inc Derivados deuterados de ivacaftor.
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
WO2013038390A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Hétérocyclyle carboxamides n-substitués
EP2755472B1 (fr) 2011-09-16 2016-08-31 Bayer Intellectual Property GmbH Utilisation de cyprosulfamide pour améliorer le rendement des plantes
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038386A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Composés hétérocycliques destinés au traitement de la mucosviscidose
JP2014527973A (ja) 2011-09-23 2014-10-23 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 非生物的な植物ストレスに対する作用剤としての４−置換１−フェニルピラゾール−３−カルボン酸誘導体の使用
GB201118704D0 (en) 2011-10-28 2011-12-14 Univ Oxford Cystic fibrosis treatment
WO2013070961A1 (fr) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison à l'atp
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
RU2644723C2 (ru) 2012-01-25 2018-02-13 Вертекс Фармасьютикалз Инкорпорейтед Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
AU2013202373B2 (en) 2012-01-25 2016-04-14 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2013112651A2 (fr) 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Composés modulant l'activité du protéasome
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
WO2013130669A1 (fr) 2012-02-27 2013-09-06 Vertex Pharmaceuticals Incorporated Composition pharmaceutique et son administration
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2013158121A1 (fr) 2012-04-20 2013-10-24 Vertex Pharmaceuticals Incorporated Formes solides de n-[2,4-bis(1,1-diméthyléthyle)-5-hydroxyphényle]-1,4-dihydro-4-oxoquinoline-3-carboxamide
MX2014014234A (es) 2012-05-22 2015-05-07 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
EP2858645A1 (fr) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques pour le traitement des troubles à médiation par cftr
WO2013185202A1 (fr) 2012-06-14 2013-12-19 Beta Pharma Canada Inc Inducteurs d'apoptose
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP2015178458A (ja) 2012-07-25 2015-10-08 杏林製薬株式会社 ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩
ES2677480T3 (es) 2012-08-13 2018-08-02 Abbvie Inc. Agentes que inducen apoptosis
US9896443B2 (en) 2012-08-21 2018-02-20 Peter Maccallum Cancer Institute Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10093640B2 (en) * 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
IL283276B1 (en) 2012-11-02 2024-01-01 Vertex Pharma Preparations containing 3-(6-(1-(2,2-difluorobenzo[1,3][D]dioxol-5-yl)cycloproponecarboxamide)-3-methylpyridin-2-yl)benzoic acid and N-(5-hydroxy- 2,4-ditert-butyl-phenyl)-4-oxo-H1-quinoline-3-carboxamide and their uses
WO2014071247A1 (fr) * 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Dérivés d'acide pyrrol-1-yl-benzoïque utiles en tant qu'inhibiteurs de myc
US9458137B2 (en) 2012-11-05 2016-10-04 Nantbioscience, Inc. Substituted indol-5-ol derivatives and their therapeutical applications
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
CA2891962A1 (fr) 2012-11-20 2014-05-03 Discoverybiomed, Inc. Correcteurs de cftr a petites molecules
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
BR112015012926A2 (pt) 2012-12-05 2017-07-11 Bayer Cropscience Ag uso de 1-(aril etinil)-, 1-(heteroaril etinil)-, 1-(heterociclil etinil)- substituído e 1-(cicloalquenil etinil)-ciclohexanóis como agentes ativos contra o estresse abiótico da planta
US20150315146A1 (en) 2012-12-05 2015-11-05 Bayer Cropscience Ag Use of substituted 1-(aryl ethynyl)-, 1-(heteroaryl ethynyl)-, 1-(heterocyclyl ethynyl)- and 1-(cycloalkenylethynyl)-bicycloalkanols as active agents against abiotic plant stress
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
US9029382B2 (en) 2012-12-17 2015-05-12 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
WO2014109858A1 (fr) 2013-01-14 2014-07-17 Amgen Inc. Méthodes d'utilisation d'inhibiteurs de cycle cellulaire pour moduler une ou plusieurs propriétés d'une culture cellulaire
BR112015023328A2 (pt) 2013-03-13 2017-07-18 Flatley Discovery Lab compostos de piridazinona e métodos para o tratamento de fibrose cística
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9815825B2 (en) 2013-03-15 2017-11-14 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
SI3660013T1 (sl) 2013-03-15 2022-05-31 Cyclerion Therapeutics, Inc. SGC stimulatorji
KR102376354B1 (ko) 2013-03-29 2022-04-04 다케다 야쿠힌 고교 가부시키가이샤 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도
WO2014180562A1 (fr) 2013-05-07 2014-11-13 Galapagos Nv Nouveaux composés et leurs compositions pharmaceutiques pour le traitement de la mucoviscidose
WO2014181287A1 (fr) 2013-05-09 2014-11-13 Piramal Enterprises Limited Composés hétérocyclyliques et leurs utilisations
CN105473578A (zh) 2013-05-24 2016-04-06 加州生物医学研究所 用于治疗抗药性和持续性结核病的化合物
EP3013341A4 (fr) 2013-06-26 2017-02-08 Proteostasis Therapeutics, Inc. Procédés de modulation de l'activité de cftr
CN105518000B (zh) 2013-07-02 2018-09-14 加州生物医学研究所 用于治疗囊性纤维化的化合物
JP6461133B2 (ja) 2013-07-15 2019-01-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規４置換及び５置換ベンゾイミダゾリウム化合物
EP3022196B1 (fr) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Composés de benzimidazolium nouveaux
EP3022198B1 (fr) 2013-07-15 2019-09-11 Boehringer Ingelheim International GmbH Nouveaux composés de benzimidazole 5-substitués
WO2015010832A1 (fr) 2013-07-22 2015-01-29 Syngenta Participations Ag Dérivés hétérocycliques microbiocides
EP3038618B1 (fr) 2013-08-28 2020-10-14 Vanderbilt University Inhibiteurs de mcl-1 de type indole substitué
US9663508B2 (en) 2013-10-01 2017-05-30 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
WO2015069287A1 (fr) 2013-11-08 2015-05-14 Allergan, Inc. Composés à utiliser en tant que modulateurs des tyrosine kinases
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CN112250627B (zh) * 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
AU2015330923B2 (en) 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
SG11201706451TA (en) 2015-02-15 2017-09-28 Hoffmann La Roche 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
CN108367002A (zh) 2015-09-21 2018-08-03 弗特克斯药品欧洲有限公司 氘化cftr增强剂的给予
EP3854782A1 (fr) 2016-03-30 2021-07-28 Genentech, Inc. Benzamides substitués et leurs procédés d'utilisation
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
BR112018070747B1 (pt) 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
EP3448842A1 (fr) 2016-04-26 2019-03-06 AbbVie S.À.R.L. Modulateurs de protéine régulatrice de conductance transmembranaire de la fibrose kystique
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
ES2954658T3 (es) 2016-06-21 2023-11-23 Proteostasis Therapeutics Inc Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR
EP3519401B1 (fr) 2016-09-30 2021-09-29 Vertex Pharmaceuticals Incorporated Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
CA3041811A1 (fr) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Composes, compositions et methodes permettant de moduler cftr
WO2018081377A1 (fr) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Dérivés n-phényl-2-(3-phényl-6-oxo-1,6-dihydropyridazine-1-yl)acétamide pour traiter la mucoviscidose
US20190248765A1 (en) 2016-10-26 2019-08-15 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
MX2019005822A (es) 2016-11-18 2019-09-09 Cystic Fibrosis Found Therapeutics Inc Pirrolopirimidinas como potenciadores de cftr.
IL277491B (en) 2016-12-09 2022-08-01 Vertex Pharma Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
BR112019012335A2 (pt) 2016-12-16 2020-03-03 Cystic Fibrosis Foundation Therapeutics, Inc. Derivados de heteroarila bicíclica como potenciadores de cftr
EP3558982A1 (fr) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Modulateurs cftr deutérés et procédés d'utilisation
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US20180280349A1 (en) 2017-03-28 2018-10-04 Vertex Pharmaceuticals Incorporated Methods of treating cystic fibrosis in patients with residual function mutations
CA3061476A1 (fr) 2017-04-28 2018-11-01 Proteostasis Therapeutics, Inc. Derives de 4-sulfonylaminocarbonylquinoleine pour accroitre l'activite du cftr
EP3634402A1 (fr) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
CA3068609A1 (fr) 2017-07-01 2019-01-10 Vertex Pharmaceuticals Incorporated Compositions et methodes de traitement de la fibrose kystique
US20200171015A1 (en) 2017-07-17 2020-06-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
EP3662079A4 (fr) 2017-07-31 2021-04-14 Technion Research & Development Foundation Limited Procédés de détection d'adn modifié et non modifié
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20210369749A1 (en) 2017-10-06 2021-12-02 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US20210228489A1 (en) 2017-12-04 2021-07-29 Vertex Pharmaceuticals Incorporated Compositions for treating cystic fibrosis
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019191620A1 (fr) 2018-03-30 2019-10-03 Vertex Pharmaceuticals Incorporated Formes cristallines de modulateurs de cftr
US20210139514A1 (en) 2018-04-05 2021-05-13 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3774825A1 (fr) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
WO2020214921A1 (fr) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Formes solides de modulateurs de cftr
WO2020242935A1 (fr) 2019-05-29 2020-12-03 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la mucoviscidose
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
AU2020328568A1 (en) 2019-08-14 2022-03-03 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
BR112022002605A2 (pt) 2019-08-14 2022-05-03 Vertex Pharma Formas cristalinas de moduladores de cftr

Also Published As

Publication number Publication date
RS60906B1 (sr) 2020-11-30
RU2017115711A (ru) 2018-11-20
CN112250627B (zh) 2024-02-02
US20180185364A1 (en) 2018-07-05
MA54649A (fr) 2022-04-27
NZ768373A (en) 2024-03-22
CL2017000824A1 (es) 2018-01-19
TWI735416B (zh) 2021-08-11
AU2015328174B2 (en) 2020-05-21
CN112279808B (zh) 2024-03-08
NZ768368A (en) 2024-03-22
US20170196862A2 (en) 2017-07-13
ES2823850T3 (es) 2021-05-10
TW202140422A (zh) 2021-11-01
EP3798214B1 (fr) 2022-09-14
US10758534B2 (en) 2020-09-01
EP3203840B1 (fr) 2020-08-05
JP2021138751A (ja) 2021-09-16
SI3203840T1 (sl) 2020-10-30
SG10201913603QA (en) 2020-02-27
KR20170064549A (ko) 2017-06-09
SG10201902963PA (en) 2019-05-30
DK3203840T3 (da) 2020-08-31
LT3203840T (lt) 2020-10-26
AU2015328174A8 (en) 2017-05-04
CN107690281A (zh) 2018-02-13
EP4159717A1 (fr) 2023-04-05
CN112250627A (zh) 2021-01-22
US10258624B2 (en) 2019-04-16
US20190269683A1 (en) 2019-09-05
US9782408B2 (en) 2017-10-10
CY1123487T1 (el) 2022-03-24
PL3203840T3 (pl) 2021-01-11
US20160095858A1 (en) 2016-04-07
TW201713617A (zh) 2017-04-16
MX2017004543A (es) 2017-10-04
UA125245C2 (uk) 2022-02-09
RU2017115711A3 (fr) 2018-12-03
EP3203840A1 (fr) 2017-08-16
JP2017530167A (ja) 2017-10-12
KR102336926B1 (ko) 2021-12-08
EP3203840A4 (fr) 2018-08-15
AU2020220185B2 (en) 2022-12-08
CA2963792A1 (fr) 2016-04-14
ZA201703054B (en) 2023-03-29
AU2020220185A1 (en) 2020-09-10
IL251517A0 (en) 2017-05-29
AU2015328174A1 (en) 2017-04-27
MA41051B1 (fr) 2020-11-30
HRP20201603T1 (hr) 2021-02-19
CO2017004538A2 (es) 2017-11-10
WO2016057572A1 (fr) 2016-04-14
US20230233560A1 (en) 2023-07-27
JP6896619B2 (ja) 2021-06-30
CN107690281B (zh) 2020-11-17
US11426407B2 (en) 2022-08-30
SG11201702817SA (en) 2017-05-30
RU2020134082A3 (fr) 2021-04-08
EP3798214A1 (fr) 2021-03-31
IL279460A (en) 2021-01-31
CN112279808A (zh) 2021-01-29
US20210052584A1 (en) 2021-02-25
RU2734876C2 (ru) 2020-10-23
BR112017007167A2 (pt) 2018-04-10
NZ730794A (en) 2024-03-22
RU2020134082A (ru) 2020-11-27
AU2023201404A1 (en) 2023-04-06
HUE051972T2 (hu) 2021-04-28
PT3203840T (pt) 2020-10-27
MX2021001903A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
MA41051A (fr) Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
MA45920A (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
EP4321513A3 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
EA202091709A1 (ru) Ингибиторы днк-пк
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
EA201790818A1 (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MA40225A (fr) Composés dihydroisoquinolinone substitués
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
EA201790904A1 (ru) Новые производные пиразола в качестве ингибиторов nik
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
EA201692003A1 (ru) Макроциклические производные пиримидина
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
EA201791030A1 (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
EA202091708A1 (ru) Ингибиторы днк-пк
WO2018136437A3 (fr) Nouveaux composés utiles en tant qu'inhibteurs de l'indoléamine 2,3-dioxygénase et/ou du tryptophane dioxygénase
MA37666B1 (fr) Sel de camsylate
EA201892264A1 (ru) Производные тетрагидроизохинолина
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
EA201692300A1 (ru) Производные карбоксамида
CY1122506T1 (el) Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη